Cov-2 Spike Protein Distances
Lab Reagents
Human IgG antibody Laboratories manufactures the cov-2 spike protein distances reagents distributed by Genprice. The Cov-2 Spike Protein Distances reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Cov-2 products are available in stock. Specificity: Cov-2 Category: Spike Group: Protein Distances
SARS-CoV spike protein Antibody |
|||
abx023139-100ug | Abbexa | 100 ug | EUR 1028.4 |
SARS-CoV spike protein Antibody |
|||
abx023143-100ug | Abbexa | 100 ug | EUR 1028.4 |
SARS-CoV-2 Spike S2 Peptide |
|||
9119P | ProSci | 0.05 mg | EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike S2 Peptide |
|||
9123P | ProSci | 0.05 mg | EUR 235.5 |
Description: (CT) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664-050 | EpiGentek | 50 ul | EUR 341 |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664-100 | EpiGentek | 100 ul | EUR 518.1 |
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680-050 | EpiGentek | 50 ul | Ask for price |
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680-100 | EpiGentek | 100 ul | EUR 882.2 |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664 | EpiGentek |
|
|
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680 | EpiGentek |
|
|
SARS-CoV Spike Antibody |
|||
3219-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3219-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3221-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3223-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
|||
3225-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |